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9Scope of this thesis
Estrogen receptor signalling,…
 The estrogen receptor is a nuclear hormone receptor that is activated by estrogens. 
The activated receptor dimerizes and binds to responsive elements on the DNA. Cofactors 
are recruited to regulate the transcription of genes.  Thereby, estrogens can induce cell 
proliferation. 
…breast cancer…
 The clinic makes clever use of this characteristic in breast cancer treatment. In about 
70% of all breast cancer cases, the tumor expresses the estrogen receptor. Patients diagnosed 
with this type of breast cancer commonly receive endocrine treatment after surgical removal 
of the tumor. Endocrine treatment can either target the receptor with competitive drugs 
(antiestrogens), or prevent formation of natural estrogens by inhibiting the aromatase 
enzyme (aromatase inhibitors). Because such tumors are dependent on estrogens for their 
growth, both treatment modalities should result in growth arrest and prevention of disease 
recurrence.
…and endocrine resistance
 Endocrine treatment in breast cancer is often successful, yet a subset of patients 
develop therapeutic resistance. This thesis focuses on one type of endocrine resistance: the 
widely used antiestrogen tamoxifen. A number of factors have been attributed to tamoxifen 
resistance, among which phosphorylation of the estrogen receptor.
 A general introduction into the role of phosphorylation of ERα in tamoxifen resistance 
is given in Chapter 1. In this review, biological and clinical data are discussed concerning known 
and putative phosphorylation sites of ERα. Phosphorylation is the addition of a phosphate 
group onto a protein, which is a bulky and negatively charged molecule. Phosphorylation 
can affect the structural conformation of the receptor. This can in turn influence ER function, 
e.g. by interfering with dimerization or by differential recruitment of coregulators. Kinases 
and molecular pathways involved in targeting these sites are briefly discussed. Some 
phosphorylation events are beneficial to tamoxifen response, whereas others may induce 
resistance. 
 Chapter 2 addresses a more fundamental question of how different structural 
domains of the estrogen receptor define its function. This was done by a comparison between 
the two receptor subtypes: ERα and ERβ. Both proteins contain two activation function 
domains, AF-1 and AF-2, separated by a hinge region. Although both are members of one 
family and are partially conserved, their differences result in different function. By swapping 
domains between ERα and ERβ, we discovered that the synergy between the AF-1 and AF-2 
domains is dependent on the hinge region. Together, the domains determine the quantitative 
response to estradiol or tamoxifen.
 The estrogen receptor requires coregulators to perform its transactivation function 
on DNA. By differential coregulator recruitment it determines which genes are transcribed 
and which are blocked. In Chapter 3 we applied a high-throughput chip containing coregulator 
motif peptides, to investigate coregulator binding by full-length ERα. This technique enabled 
us to study both overexpressed and endogenous proteins in lysates from different cell lines. 
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Moreover, peptide binding was measured in crude lysates from patient tumor tissue.
 Phosphorylation of the estrogen receptor can affect its function by altering coregulator 
recruitment. Therefore, we investigated if protein kinase A (PKA) induced phosphorylation of 
the ERα Serine 305 residue, which has been associated with tamoxifen resistance, influences 
coregulator binding. Phosphorylation resulted in enhanced coregulator interactions.
 How does phosphorylation of ERα result in a conformational change and differential 
recruitment of coregulators ultimately lead to cell proliferation, tumor growth and tamoxifen 
resistance? Chapter 4 addresses these questions by genome wide analyses of the chromatin 
binding landscape and gene expression profile of cells expressing Serine 305 phosphorylated 
ERα. We discovered that one post-translational modification, i.e. ERα Ser305 phosphorylation, 
can dramatically influence the chromatin binding preferences of the receptor, here showing 
a strong enrichment at promotor start sites, 3’ and 5’ UTRs. We defined a 100-gene classifier, 
and determined distinct targets for the phosphorylated receptor, including MYC, a known 
oncogene. A differential regulation of the MYC pathway could very well explain resistance to 
tamoxifen. This suggestion is supported by the significant correlation of the classifier with poor 
disease outcome in two independent datasets of ERα positive, tamoxifen treated patients.
 Finally, Chapter 5 puts the work presented in this thesis in perspective and provides 
an outlook for future studies.
